Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2000
11/07/2000US6143730 As anti-angiogenic, anti-metastatic and/or anti-inflammatory agents
11/07/2000US6143728 Guanylhydrazones useful for treating diseases associated with T cell activation
11/07/2000US6143715 For treating and prevention of hepatitis c viurs infections
11/07/2000US6143544 Human lysophospholipase
11/07/2000US6143521 Human bombesin receptor subtype-3sb
11/07/2000US6143314 Thermoplastic resin
11/07/2000US6143306 Methods for treating pancreatic disorders
11/07/2000US6143292 Allogeneic cell therapy for cancer following allogeneic stem cell transplantation
11/07/2000US6143287 Applying a mixture of liposome and phthalocyanine; applying light source
11/07/2000US6143279 Uridine 5'-diphosphate and analogs useful for treating lung diseases
11/07/2000US6143278 Topical administration of opioid analgesic agent in admixture with skin or mucosal specific penetration enhancer to produce localized analgesic effect in skin or mucosal tissue without transdermal migration of opiod agent
11/07/2000US6143276 Methods for delivering bioactive agents to regions of elevated temperatures
11/07/2000CA2170485C Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agents and caffeine
11/07/2000CA2037933C Method of treatment with medical agents
11/03/2000CA2270600A1 Method and formulations for the treatment of diseases, particularly those caused by human immunodeficiency virus and leishmania
11/02/2000WO2000066152A1 A pharmaceutical formulation containing an inhibitor of carboxypeptidase u and a thrombin inhibitor
11/02/2000WO2000065346A1 Diagnosis of human kidney diseases
11/02/2000WO2000065069A1 Dsp-5 dual-specificity map kinase phosphatase
11/02/2000WO2000065068A1 Dsp-10 dual-specificity map kinsase phosphatase
11/02/2000WO2000065054A2 Human membrane-associated proteins
11/02/2000WO2000065046A1 Pollinosis-associated gene 373
11/02/2000WO2000065045A1 Pollinosis-associated gene 419
11/02/2000WO2000064946A2 Compositions and methods for cancer treatment by selectively inhibiting vegf
11/02/2000WO2000064944A1 Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains
11/02/2000WO2000064932A1 Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides
11/02/2000WO2000064485A2 Specifically targeted catalytic antagonists and uses thereof
11/02/2000WO2000064479A1 Compositions containing tetracyclines for treating hemorrhagic virus infections and other disorders
11/02/2000WO2000064472A1 Methods and compositions for treating dermatological disorders with fruit extracts
11/02/2000WO2000064469A2 Use of glucose-6-phospate isomerase and antibodies thereto for the diagnosis and therapy of arthritis, and test of anti-arthritic compounds
11/02/2000WO2000064468A2 Therapeutic compositions and methods for enhancing angiogenesis
11/02/2000WO2000064465A1 Death domain containing receptors
11/02/2000WO2000064455A1 Method of enhancing the efficacy of anti-tumor agents
11/02/2000WO2000064451A1 Use of tagatose to enhance key blood factors
11/02/2000WO2000064441A2 Compound for use as a medicament for treatment of disorders involving bronchocontraction
11/02/2000WO2000064425A2 Miotic agents and hypertonic agents containing ophthalmic compositions
11/02/2000WO2000064422A2 Novel treatment of neurotraumatic conditions with raf inhibitor
11/02/2000WO2000064418A2 Transdermal therapeutic system with neutralized acrylic adhesive patch
11/02/2000WO2000064414A2 Solid pharmaceutical formulations of acid-sensitive proton-pump blockers
11/02/2000WO2000064260A1 Compositions and methods for treatment of hyperproliferative diseases
11/02/2000WO2000042987A3 Targeted vesicular constructs for cytoprotection and treatment of h. pylori infections
11/02/2000WO2000042216A3 Genetic predisposition to abnormal calcification conditions
11/02/2000WO2000042042A3 High affinity inhibitors for target validation and uses thereof
11/02/2000WO2000041516A3 Reagents and methods useful for detecting diseases of the breast
11/02/2000WO2000040172B1 Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents
11/02/2000WO2000039279A3 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof
11/02/2000WO2000039143A3 Antiviral nucleoside analogues
11/02/2000WO2000039136A3 Human brainiac-5
11/02/2000WO2000038730A3 Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
11/02/2000WO2000038626A3 Substrate composition and method of use for sequestration of skin irritants
11/02/2000WO2000037640A9 Compositions and methods for the treatment of tumor
11/02/2000WO2000029029A9 Compositions and methods for producing vascular occlusion
11/02/2000WO2000018917A3 α-SYNUCLEIN SUPER-MUTANTS ACCELERATE α-SYNUCLEIN AGGREGATION
11/02/2000EP1048299A1 Method for inhibiting cell functioning for use in anti-inflammatory and anti-tumour therapies
11/02/2000EP1048285A2 Composition for eyebrow pencil with agglomerated pigments
11/02/2000EP1047788A2 Metastatic breast and colon cancer regulated genes
11/02/2000EP1047787A1 Human calcineurin b-like protein
11/02/2000EP1047785A1 Modified deacetoxycephalosporin c synthase (daocs) and x-ray structure
11/02/2000EP1047782A1 Interleukin-1 receptor antagonist beta (il-1ra beta)
11/02/2000EP1047776A2 Therapeutic composition comprising the kal protein and use of the kal protein
11/02/2000EP1047770A1 Histidine kinase
11/02/2000EP1047712A1 Fatty acid synthase mrna binding protein
11/02/2000EP1047471A1 Systems and methods for local delivery of an agent
11/02/2000EP1047456A1 A method and composition for cancer treatment by enzymatic conversion of soluble radioactive toxic agents
11/02/2000EP1047454A1 Methods of screening compounds useful for prevention of infection or pathogenicity
11/02/2000EP1047452A1 Conjugates comprising two active agents
11/02/2000EP1047450A1 Ace inhibitor-mmp inhibitor combinations
11/02/2000EP1047444A1 Methods of neuroendocrine regulation of affective disorders
11/02/2000EP1047436A2 Methods of treating tardive dyskinesia and other movement disorders
11/02/2000EP1047432A1 Drug-directed mutagenesis/drug-driven selection for lethal mutants
11/02/2000EP1047427A1 Combination of a gaba-a alpha 2/3 agonist and a selective serotonin reuptake inhibitor
11/02/2000EP1047425A1 Integrin receptor antagonists
11/02/2000EP1047422A1 Use of histamine for elevating blood histamine levels
11/02/2000EP1047421A2 Inhibition of lipoprotein oxidation
11/02/2000EP1047410A1 Treatment of glc1a glaucoma with non-steroidal glucocorticoid antagonists
11/02/2000EP0848592B1 Antistress agents for aquatic animals
11/02/2000EP0626844B1 Compositions of clindamycin and benzoyl peroxide for acne treatment
11/02/2000DE19917990A1 Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk Medicines containing inhibitors of cell volume-regulated human kinase h-sgk
11/02/2000CA2377135A1 Dsp-10 dual-specificity map kinsase phosphatase
11/02/2000CA2371242A1 Diagnosis of human kidney diseases
11/02/2000CA2371217A1 A pharmaceutical formulation containing an inhibitor of carboxypeptidase u and a thrombin inhibitor
11/02/2000CA2371114A1 Death domain containing receptors
11/02/2000CA2371046A1 Therapeutic compositions and methods for enhancing angiogenesis
11/02/2000CA2370895A1 Miotic agents and hypertonic agents containing ophthalmic compositions
11/02/2000CA2370547A1 Dsp-5 dual-specificity map kinase phosphatase
11/02/2000CA2370306A1 Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains
11/02/2000CA2370195A1 Human membrane-associated proteins
11/02/2000CA2369951A1 Solid pharmaceutical formulations of acid-sensitive proton-pump blockers
11/02/2000CA2369910A1 Compositions and methods for treatment of hyperproliferative diseases
11/02/2000CA2368213A1 Specifically targeted catalytic antagonists and uses thereof
11/01/2000CN1272058A Perforated microparticles and methods of use
11/01/2000CN1271579A Compound vitamin for health of cardiovascular
11/01/2000CN1057908C Use of hyaluronic acid and forms to prevent arterial restenosis
10/2000
10/31/2000US6141589 Switch control for external pacing system
10/31/2000US6140488 Ras-binding protein (PRE1)
10/31/2000US6140364 Arachidonic acid metabolite, 16-HETE
10/31/2000US6140363 Administering rosmarinic acid, its derivative or prunella vulgaris extract for suppressing immune response for treatment, prevention, or diagnosis of rejection of transplanted organ or tissue, chronic rejection
10/31/2000US6140357 Small molecule inhibitors of rotamase enzyme activity
10/31/2000US6140343 Cholesteryl ester transfer protein inhibitors which are used to elevate highdensity lipoprotein-cholesterol and to lower low density lipoprotein-cholesterol and triglycerides; for treating atherosclerosis, peripheral vascular disease, obesity
10/31/2000US6140337 Methods for the treatment of mental disorders
10/31/2000US6140324 Use of a tachykinin antagonist and a muscarinic antagonist and/or an antihistamine to treat motion sickness
1 ... 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 ... 1151